Rituximab: all 1,386 studies that test it
Page 13 of 14. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.
- Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's LymphomaTerminatedNCT00367497Phase 2
- Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic LeukemiaCompletedNCT00366418Phase 1
- Rituximab Treatment in Sjogren's SyndromeCompletedNCT00363350Phase 1/2
- Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's LymphomaCompletedNCT00347971Phase 1
- Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)CompletedNCT00346684Phase 2
- Rituximab as Second Line Treatment for ITPCompletedNCT00344149Phase 3
- Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic LeukemiaWithdrawnNCT00343447Phase 2
- Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic LeukemiaCompletedNCT00337246Phase 2
- Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's LymphomaCompletedNCT00334438Phase 1
- A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.Status unknownNCT00333008Phase 2
- Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLLCompletedNCT00330252Phase 1
- GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaSuspendedNCT00324831Phase 3
- Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic LeukemiaCompletedNCT00324779Phase 2
- Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid TreatmentStatus unknownNCT00324467Phase 2
- Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's LymphomaWithdrawnNCT00310128Phase 2
- Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)CompletedNCT00309881Phase 2
- RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing VasculitidesCompletedNCT00307593Not applicable
- Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaTerminatedNCT00301795Phase 2
- Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System LymphomaStatus unknownNCT00293475Phase 1/2
- Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and VasculitisCompletedNCT00293072Phase 2
- Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell LymphomaCompletedNCT00290667Phase 2
- Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 YearsCompletedNCT00285389Phase 2
- Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic LeukemiaTerminatedNCT00281931Phase 2
- Rituximab in Combination With Outpatient Therapy for CD20+ LymphomaCompletedNCT00280878Phase 2
- Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00278421Phase 3
- Pilot Study of Rituximab for Membranoproliferative GlomerulonephritisCompletedNCT00275613Phase 1
- Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic LeukemiaCompletedNCT00275054Phase 3
- Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic LeukemiaCompletedNCT00274989Phase 2
- VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHLCompletedNCT00274794Not applicable
- Immunopharmacological Effects of Rituximab in Atopic DermatitisCompletedNCT00267826Not applicable
- Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaTerminatedNCT00265928Phase 2
- Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic LeukemiaTerminatedNCT00265915Phase 2
- Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell LymphomaStatus unknownNCT00261612Phase 2
- Rituximab Treatment to Block HLA Antibodies in Renal Transplant RecipientsWithdrawnNCT00261547Phase 1/2
- Rituximab in Active Ulcerative ColitisCompletedNCT00261118Phase 2/3
- RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal GammopathyCompletedNCT00259974Phase 3
- A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal EncephalitisCompletedNCT00259805Phase 1
- Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's LymphomaStatus unknownNCT00258336Phase 2
- Safety and Efficacy Study of Rituximab in Renal TransplantationCompletedNCT00255593Phase 1
- Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular LymphomaCompletedNCT00251394Phase 2
- Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic PurpuraWithdrawnNCT00251277Phase 1/2
- Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's LymphomaTerminatedNCT00250861Phase 2
- Effectiveness of Rituximab in Pediatric OMS Patients.CompletedNCT00244361Phase 1/2
- Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.Status unknownNCT00244127Phase 2
- Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell LymphomaCompletedNCT00242996Phase 2
- Rituximab in Treating Patients With Follicular Non-Hodgkin's LymphomaCompletedNCT00227695Phase 3
- Study of the Effectiveness of Rituximab in Adults With Chronic and Severe Immune Thrombocytopenic Purpura and Candidate for a SplenectomyTerminatedNCT00225875Phase 2
- Safety Study of Rituximab (Rituxan®) in Chronic UrticariaTerminatedNCT00216762Phase 1/2
- Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaTerminatedNCT00216164Phase 2
- A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal TransplantationCompletedNCT00214266Phase 2
- Effect of Anti CD20 in Pemphigus DeseaseCompletedNCT00213512Phase 2/3
- Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's LymphomaCompletedNCT00210379Phase 2
- A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous MeningitisWithdrawnNCT00210340Phase 1
- Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00204659Phase 2
- Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic LeukemiaCompletedNCT00201721Phase 2
- Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaCompletedNCT00201682Phase 1/2
- Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in AdultsCompletedNCT00199082Phase 4
- Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and RituximabCompletedNCT00199004Phase 4
- German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00198978Phase 4
- Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00193466Phase 2
- Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's LymphomaCompletedNCT00193440Phase 2
- Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell LymphomaTerminatedNCT00183989Phase 2
- Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALLTerminatedNCT00180895Phase 2
- LMBA02 Protocol for Patients With a Burkitt LymphomaStatus unknownNCT00180882Phase 3
- Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseTerminatedNCT00176475Phase 1
- Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's LymphomaCompletedNCT00169208Phase 2
- Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell LymphomaTerminatedNCT00169169Phase 3
- A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic LymphomaCompletedNCT00169156Phase 2
- Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell LymphomaCompletedNCT00169143Phase 2
- Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)CompletedNCT00168740Phase 3
- Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney TransplantWithdrawnNCT00167791Not applicable
- A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan AloneWithdrawnNCT00161564Phase 2
- Rituximab in the Treatment of Graves' DiseaseCompletedNCT00150111Phase 1/2
- Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's LymphomaCompletedNCT00147953Phase 2
- ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell LymphomaCompletedNCT00144807Phase 2
- Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's LymphomaCompletedNCT00143871Phase 2
- Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00143065Phase 2
- Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's MacroglobulinemiaCompletedNCT00142155Not applicable
- Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's LymphomaTerminatedNCT00141700Phase 2
- ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell LymphomaTerminatedNCT00140660Phase 3
- ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1CompletedNCT00140595Phase 3
- Primary Rituximab and MaintenanceCompletedNCT00140582Phase 3
- Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor BurdenCompletedNCT00136552Phase 3
- Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host DiseaseCompletedNCT00136396Phase 1/2
- Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.Status unknownNCT00131313Phase 4
- Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on ChemotherapyTerminatedNCT00127569Phase 2
- Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's LymphomaTerminatedNCT00126243Phase 2
- Chemotherapy Followed by Zevalin for Relapsed Mantle Cell LymphomaCompletedNCT00119730Phase 2
- Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaCompletedNCT00117975Phase 2
- Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular LymphomaCompletedNCT00115700Phase 3
- Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaCompletedNCT00112931Phase 3
- Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's LymphomaWithdrawnNCT00110006Not applicable
- Anti-CD20 Antibody Therapy for Sjogren's SyndromeCompletedNCT00101829Phase 1
- Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00100737Phase 2
- 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaTerminatedNCT00098488Phase 1
- A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple SclerosisCompletedNCT00097188Phase 2
- Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00093769Phase 2
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityActive, not recruitingNCT00092222Phase 2
- Rituximab to Treat Stiff Person SyndromeCompletedNCT00091897Phase 2
- Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's LymphomaCompletedNCT00090038Phase 4